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Summary. Epidermal growth factor receptor (EGF-R) 
was studied with monoclonal antibody 2E9 on 50 ovarian 
tumors of various histological types and 10 non-tumor- 
ous ovarian tissues by immunohistochemistry. Enhanced 
expression was observed in 26/50 (52%) of the tumors. 
Only 25 out of 46 epithelial tumors (54%) showed posi- 
tivity in epithelial tumor cells. Staining was cytoplasmic 
in all cases. No correlation was established between 
EGF-R expression and the histological type of the epithe- 
lial tumor. Apart from EGF-R expression i  tumor cells, 
low immunoreactivity was also observed in stromal and 
endothelial cells in both normal and tumorous ovarian 
tissues. Furthermore in 8/9 specimens containing ne- 
crotic areas, EGF-R was noticed in these areas as well. 
Both of the latter observations may have impact on the 
evaluation of the prognostic value of EGF-R activity in 
tumors, when based on EGF-R measurements u ing bio- 
chemical binding studies. We therefore recommend that 
EGF-R is measured with both methods in studies regard- 
ing its clinical value. 
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Introduction 
Although the management of patients with advanced 
ovarian cancer has improved, the prognosis remains poor 
(Neyt et al. 1985): the 10-year survival rate of patients in 
Figo stages III and IV following cisplatin-containing che- 
motherapy is only 20% (Sutton et al. 1989). Therefore, 
new treatment modalities are urgently needed. In the last 
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few years much attention has been focussed on the role 
of growth factors and their receptors in the development 
and biology of cancer (Greig et al. 1988). Evidence xists 
that the presence of growth factor receptors on tumor 
cells may be of importance with respect o the clinical 
outcome of several malignancies (Greig et a. 1988). The 
prognostic value of epidermal growth factor receptors 
(EGF-R) is especially under discussion in breast cancer 
(Sainsbury et al. 1987; Foekens et al. 1989; Nicholson et 
al. 1989). 
In ovarian cancer, data on EGF or their receptors are 
limited. Bauknecht et al. (1989a, b) and Battaglia et al. 
(1989) reported EFG-R positivity in 36% (n = 101), 45% 
(n -= 141) and 75 % (n = 24) of patients respectively. What 
is important is that the presence of these receptors ap- 
peared to be of prognostic significance in the studies of 
Bauknecht et al. (1989 a, b). These studies with respect to 
EGF-R in ovarian (cancer) tissues were performed using 
biochemical binding assays on membrane homogenates 
only. Since heterogeneity in the distribution of EGF-R 
within an individual tumor cannot be determined by bio- 
chemical methods we have focussed on the immunohisto- 
chemical examination both of different histological sub- 
types of ovarian cancer and of normal ovarian tissues for 
the incidence and distribution of EGF-R. 
Materials and methods 
Fifty tumors and 10 non-tumorous ovaries were analyzed. Tumors 
were classified according to the WHO classification 1973 (Serov and 
Scully 1973). Fifteen patients (mean age 57 years) had a serous 
adenocarcinoma, 6 patients (mean age 50 years) had a mucinous 
adenocarcinoma, 11 patients (mean age 53 years) had an endome- 
troid carcinoma, 4 patients (mean age 55 years) had a clear-cell car- 
cinoma, 3 patients (mean age 50 years) had a poorly differentiated 
carcinoma, 3 patients (mean age 47 years) had borderline malignant 
epithelial tumors (1 serous, 2mucinous) and 4 patients (mean age 
65 years) benign epithelial tumors (2 serous, 1 mucinous cys- 
tadenoma, nd i adenofibroma). Apart from these pithelial tumors 
4 patients (mean age 41 years) had non-epithelial ovarian tumors [3 
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sex cord tumors (1 granulosa cell and 2 thecoma) and 1 germ-cell tu- 
mor (immature teratoma)]. 
Representative tissue samples were snap-frozen in liquid ni- 
trogen and stored at - 70 ~ C until use. Serial sections were cut 4 gm 
thick. These were air-dried an fixed in acetone for 10 rain, after 
which the indirect immunoperoxidase technique was used. Briefly, 
after rinsing for 15 rain in phosphate-buffered saline (PBS), in the 
first step, monoclonal ntibody 2E9 (Defize et al. 1987, 1989) IgG1 
[Anti-(protein core)low-affinity EFG-R, extracellular domain; gen- 
erously provided by Dr. L.H.H. Defize, Hubrecht Laboratory 
Utrecht, The Netherlands] was applied on sections for 24 h at 4 ~ C 
(50 gg/ml). After rinsing with PBS for 15 min, the second antibody, 
borseradish-peroxidase-conjugated rabbit anti-(mouse IgG) (Dako) 
(dilution 1:160), was applied for 30 rain. After washing, peroxidase 
staining with DAB-H202 and rinsing in PBS, sections were counter- 
stained with haemalum and mounted with malinol. All immunore- 
agents were diluted inPBS containing 2% normal human serum and 
normal rabbit serum. Control sections consisted of known positive 
and negative specimens identified by ligand-binding assay. In addi- 
tion, in one negative control section the first-layer antibody was 
changed to PBS or non-immune ascites fluid. 
. Intensity of immunohistochemical st ining was subjectively esti- 
mated as negative (0), very weakly _+ or weakly positive +, moder- 
ately positive + , or strongly positive + + . The percentages of
stained tumor cells were noted in categories of 5%-25%, 26%- 
50%, 51%-75%, and >75%. 
Table 1. Expression of epidermal growth factor receptor (EGF-R) 
in ovarian tumors 
Tissue type EGF-R" Total no. 
of cases 
= 
Epithelial ovarian tumors 
Serous carcinoma 6 9 
Mucinous carcinoma 1 5 
Endometrioid carcinoma 5 6 
Clear-cell carcinoma 3 1 
Poorly differentiated 2 1 
carcinomas 
Borderline serous 1 0 
Borderline mucinous 0 2 
Benign serous 1 i 
Benign mucinous 1 0 
Adenofibroma 1 0 
Other ovarian tumors 
Sex cord tumors 
Granulosa cell 1 0 
Thecoma 2 0 
Germ-cell tumors 
Immature teratoma 
Total 
15 
6 
11 
4 
3 
0 1 1 
24 26 (52%) 50 
" EGF-R =, not enhanced in tumor cells when compared to 
intrinsic stromal component; EGF-R 1', enhanced expression of 
EGF-R in tumor cells when compared to intrinsic stromal com- 
ponent 
Fig. 1. A Detail of normal ovarian tissue: a very weak staining of 
stromal and endothelial cells (haemalum counterstained, 250 x ). 
B Detail of poorly differentiated carcinoma. A strong staining is no- 
ticed in tumor cells. Stromal cells do stain very weakly (haemalum 
counterstained, 250 x ) 
Results 
In non-tumorous ovaries (n = 10), apart from surface ep- 
ithelial cells, spindle-shaped strornal cells and endothelial 
cells of  the vessel walls within the cortical or medullary 
area often (9/10) showed very weak (_+) or sometimes 
weak (+)  immunoreactivity for EGF-R  in vessel walls. 
Corpora albicans and intercellular collagen did not react 
at all (Fig. 1 A). A similar staining pattern was observed 
in the stromal component of  most (34/50; 68%) tumor 
specimens (Fig. 1 B). The immunostaining results of  50 
tumors of  the various histological subtypes are summa- 
rized in Table I. 
Regarding epithelial ovarian tumors, an increased im- 
munoreactivity for EGF-R  in tumor cells was noticed in 
25/46 (54%) of  the specimens examined (see Table 1). 
Staining was intracellular (cytoplasmic) in all cases. In- 
tensity of  staining varied from weak (+)  to strong 
(+ + +)  (Fig.2). The distribution of  stained cells ap- 
peared heterogeneous, varying from the focal or mosaic 
type in 18 cases, to the diffuse type in 7 cases. Immu- 
noreactivity was considered negative (not above stroma 
level) in 21 cases. No  clear correlation was found between 
enhanced expression of  EGF-R  from the staining pat- 
tern, either with respect o the staining intensity (Fig. 2) 
or to the percentage of  positive cells (Fig. 3), and the his- 
tological type of  the tumor. Regarding the other ovarian 
tumors examined, apart from one immature teratoma 
with an evident epithelial component,  no clear enhanced 
expression of  EGF-R  was noticed in the cells of  one gra- 
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nulosa cell tumor and two thecomas. In 9 tumor spec- 
imens necrotic areas were present9 In these necrotic areas 
often (8/9) a very weak to weak immunoreactivity was 
noticed as well. 
Discuss ion  
A number of monoclonal EGF-R antibodies have been 
raised by various investigators. Some of these react to a 
carbohydrate determinant that is closely related to the 
human blood group A antigen. This may be a source of 
misinterpretation. Since antibody 2E9 is reactive to the 
protein core of the EGF-R molecule, cross-reactivity 
with the blood group A antigen does not occur. In addi- 
tion, 2E9 has been shown to block binding of EGF to its 
low-affinity receptor without interfering with EGF bind- 
ing to its high-affinity receptor (Defize et al. 1989). 
In this study we demonstrate he presence of EGF-R 
in 22/39 (56%) adenocarcinomas (Table 1). This inci- 
dence is between those indicated by biochemical data, 
which have been obtained by radioligand-binding assay 
on membrane homogenates a described by Bauknecht et 
al. (1989 a, b)(45% EGF-R positivity in 141 ovarian tu- 
mors), and Battaglia et al. (1989) (75% EGF-R positivity 
in 24 ovarian tumors). 
In our study using immunohistochemistry, theposi- 
tive incidence of EGF-R was not clearly different among 
the histological subtypes (Figs. 2, 3), but some subgroups 
are relatively small. Bauknecht et al. (1988) reported a
positive association of EGF-R activity with endometri- 
oid carcinomas (5/8 EGF-R positive) and a negative as- 
sociation with clear-cell carcinomas (8/8 EGF-R nega- 
tive). This discrepancy remains at present unclear, but 
may be due to the different echniques used to assay 
EGF-R, or to the low number of patients in the various 
subclasses in both studies. 
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Whether or not EGF-R positivity is associated with 
malignant transformation of epithelial ovarian tumors is 
difficult to answer. The number of benign and borderline 
malignant tumors examined in our study is too small to 
allow any conclusion, and these tumors were not in- 
cluded in the studies of Bauknecht et al. (1988, 1989 a, b) 
and Battaglia et al. (1989). 
The cytoplasmic localization of EGF-R, as shown in 
our study and also reported by others in other types of 
tissue (Damjanov et al. 1989; Yasui et al. 1988; Nono- 
mura et al. 1988) may reflect internalization of receptor, 
a rapid process that occurs afterJigand binding, but may 
also represent newly biosynthesized EGF-R molecules 
within the Golgi that have yet to be processed and in- 
serted into the cell membrane. 
A striking finding was the binding of 2E9 to stromal 
and blood vessel endothelial cells in most "normal" 
ovaries (9/10) and in 34/50 tumor specimens studied. The 
intensity of stroma staining was very weak (__+), whereas 
in endothelial cells of the vessel walls it was very weak _+ 
to weak (+).  Staining of the stroma and vessel walls has 
also been described by Shiurba et al. (1988) in endothelial 
cells of meningeomas nd by Damjanov et al. (1989) in 
a variety of normal human tissues. Differences in staining 
intensity (shown in the study of Shiurba et al. 1988; to 
slightly above background in the study of Damjanov et 
al. 1989) may be due to either the different antibodies or 
the different echniques used. The presence of EGF-R in 
human fibroblasts has also been reported by Carlin et al. 
(1982) and Green et al. (1985), as has the presence of 
EGF-R in endothelial cells (Schreiber et al. 1986; Gospo- 
darowicz et al. 1978; Knedler and Han 1987). It was sug- 
gested that EGF may induce proliferation of (human) en- 
dothelial cells in vivo (Schreiber et al. 1986) and in vitro 
(Gospodarowicz etal. 1978; Knedler et al. 1987). 
Apart from EGF-R staining of epithelial and stromal 
cells, necrotic areas may be stained as well. Non-specific 
immunohistochemical reactivity is common in areas of 
tissue necrosis. Still the observation is in line with the au- 
toradiographic results of Reubi and Torhorst (1988) in 
human breast cancer. Therefore, it might be specific after 
all, possibly indicating the presence of membrane rem- 
nants in the necrotic areas. 
Both observations may be of importance with respect 
to the prognostic evaluation of tumors based on EGF-R 
measurements using biochemical binding assays. The 
measurement of EGF-R should therefore also be consid- 
ered using methods allowing clear identification of 
EGF-R in tumor cells. 
The role of EGF-R is still poorly understood in both 
the normal and the diseased state. As a result of EGF 
binding there is increased DNA synthesis, and cell pro- 
liferation (Gospodarowicz et al. 1983; Bauknecht et al. 
1986). Recently it has been reported that extracts of sev- 
eral gynecological malignancies, including ovarian tu- 
mors, show growth-promoting activity in vitro and are 
able to compete with EGF-R (Reubi and Torhorst 1988; 
Gospodarowicz etal. 1983). In human breast (Sainsbury 
et al. 1987; Nicholson et al. 1989), bladder (Neal et al. 
1985) and stomach cancer (Yasui et al. 1988) EGF-R ex- 
pression may identify a subclass of more aggressive tu- 
mors with a high metastatic potential. This would be even 
more so if EGF and EGF-R are synchronously 
expressed, suggesting autocrine regulation. The findings 
of Battaglia et al. (1989) showing higher levels of EGF-R 
in less differentiated ndometroid carcinoma s well as in 
metastatic ovarian carcinoma support this hypothesis. 
Bauknecht et al. (1989 b, 1990) suggests a more favorable 
response to chemotherapy in case of EGF-R positivity in 
ovarian carcinomas, but there was no effect on survival. 
The significance of EGF-R in ovarian carcinomas, in a 
cohort of patients treated in a uniform way according to 
the stage of the disease, awaits further study. At present 
we aim to measure EGF-R by both biochemical and 
immunohistochemical methods in larger series of pa- 
tients and to correlate the results with each other and 
with the prognosis. 
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